Our Unit has surpassed two centers from the United States in the randomization of patients included in a clinical trial with a neuromodulator. In addition, the sum of our activity in Sant Cugat and in Manresa has reached more than 73% of the all patients included in Spain.
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
This study could improve the efficacy and safety of the products being evaluated to try…
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
Grifols has reported to the press the positive result of the AMBAR trial in patients…
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in…
© 2022–2026 - UDIC - Unitat d'Investigació Clínica, SL · Soporte técnico
No dude en contactarnos
(+34) 931 751 575
(+34) 935 656 000 ext 1756
(+34) 651 891 344
info@udic.es
